- Home
- ELUT vs IXHL Comparison
ELUT vs IXHL Comparison
Compare ELUT & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ELUT | IXHL |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Medical Specialities | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.5M | 37.0M |
| IPO Year | 2020 | 2024 |
Fundamental Metrics
Financial Performance| Metric | ELUT | IXHL |
|---|---|---|
| Price | $0.93 | $3.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 54.4K | ★ 74.7K |
| Earning Date | 05-08-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 146.77 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,293,000.00 | $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.83 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $0.16 |
| 52 Week High | $1.51 | $6.39 |
Technical Indicators
Market Signals| Indicator | ELUT | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 47.42 | 51.90 |
| Support Level | $0.84 | $2.79 |
| Resistance Level | $1.04 | $3.68 |
| Average True Range (ATR) | 0.08 | 0.19 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 29.88 | 33.37 |
Price Performance
Historical ComparisonAbout ELUT Elutia Inc.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.